2 results
Approved WMOCompleted
The study will investigate the safety and efficacy of emicizumab in patients with hemophilia A with inhibitors against FVIII.
Approved WMOCompleted
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…